Climb Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Climb Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-212.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 92% of Healthcare companies in United States.
Cash Cushion Ratio
+17%Cash, after subtracting all debt, equals 17% of its market value (net cash).
Higher than 59% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Climb Bio, Inc. made a loss over the last year. Climb Bio, Inc. owes $0.03 for every $1 it owns. Climb Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossClimb Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.53The share price is 2.53 times Climb Bio, Inc.'s book value per share, lower than 51% of Healthcare companies in United States.
Market cap
$605 MThe total market value of all of Climb Bio, Inc.'s shares at today's price (share price × number of shares), larger than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$240 MWhat Climb Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.17Net worth divided by the number of shares. The share price of $10.54 is 2.5 times this, which is the P/B above.
Return on equity (ROE)
-27.1%Climb Bio, Inc. lost 27.1% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
Owes vs Owns
0.03×Climb Bio, Inc. owes $0.03 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Dividend yield
NoneClimb Bio, Inc. does not currently pay a dividend.
Profit growth
LossClimb Bio, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashClimb Bio, Inc. held $101 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Climb Bio, Inc.: $605 M ÷ $240 M (30 Jun 2026) = 2.5.
What is Climb Bio, Inc.'s return on equity?
Climb Bio, Inc. lost 27.1% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
How much does Climb Bio, Inc. owe compared with what it owns?
Climb Bio, Inc. owes $0.03 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Does Climb Bio, Inc. pay a dividend?
No. Climb Bio, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.